Laparoscopic cholecystectomy
ProcedureLaparoscopic cholecystectomy within 2 weeks after endoscopic removal of common bile duct stone
NCT Number: NCT07001423
The goal of this study is to compare safety and efficacy of laparoscopic cholecystectomy versus wait-and-see policy after endoscopic removal of common bile duct stones in elderly. The primary endpoint is a composite outcome: Death or major postoperative complications or recurrent biliary disease within 1 year after randomization.
Interested in participating?
Request Info75 year and older
All sexes
Interventional
Not applicable
Helsinki University Hospital, Jorvi, Espoo, Finland
Elderly patients with common bile duct stones are asked to participate this randomized trial after successful endoscopic removal of common bile duct stones. The hypothesis of the study is that wait-and-see policy is non-inferior to laparoscopic cholecystectomy. Four hundred patients are randomized 1:1 to either laparoscopic cholecystectomy group or wait-and see group. Cholecystectomy is done on the same admission or within two weeks after randomization. One interim analysis is planned for the trial after 100 randomized patients to assess safety. The trial is terminated if there is a statistically significant difference in primary outcome with p<0.001 (chi-square test) between the study arms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Laparoscopic cholecystectomy within 2 weeks after endoscopic removal of common bile duct stone
Time frame: From randomization to 1 year
The primary outcome is a composite outcome including death within 1 year after randomization, the occurrence of major complications within 30 days from surgery and recurrent biliary event requiring hospitalization. within 1 year after randomization. A recurrent biliary event refers to cholecystitis, pancreatitis, cholangitis, or bile duct stones. Major complications were defined as infectious, cardiovascular and pulmonary complications, and surgical complication (Clavien-Dindo grade III or higher)
Time frame: From randomization to 1 year
Number of days alive and out of hospital
Time frame: at 30 days, 180 days and 365 days after randomization
Quality of life is measured using EuroQOL EQ-5D-5L instrument, EQ VAS values are compared. 0 represents the worst health a person can imagine and 100 represents the the best health a person can imagine. EQ-5D-5L dimension responses are reported as a descriptive data
Time frame: From randomization to 1 year
Survival is measured using Kaplan-Meier analysis
Time frame: From randomization to 1 year
Number of patients with major complications defined as infectious, cardiovascular, and pulmonary complications, and surgical complication (Clavien-Dindo grade III or higher)
Time frame: From randomization to 1 year
Number of patients with recurrent biliary event (cholecystitis, pancreatitis, cholangitis, or symptomatic bile duct stones)
Time frame: From randomization to 2 years
The same as primary outcome, but after 2 years follow-up
Time frame: At 30, 180 and 365 days after randomization
Uncomplicated biliary pain/ post cholecystectomy pain. Specific 5 criteria of biliary pain include : 1. severe pain attacks, 2. lasting 15 to 30 minutes or longer, 3. location in epigastrium or right upper quadrant, 4. pain radiating to the back, 5. a positive pain response to simple analgesics
Time frame: From randomization to 1 year
Healthcare costs related to bile stones; including laboratory tests, imaging (ultra sound, computer tomography, magnetic resonance imaging), procedures (Endoscopic Retrograde Cholangio Pancreatography (ERCP), laparoscopic cholecystectomy), emergency visits and hospital days.
Contact information is provided by the study sponsor or research team.
Panu Mentula, MD, PhD
CONTACT
Päivi Siironen, MD, PhD
CONTACT
Helsinki University Central Hospital
Other
Acronym: COFFEE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07176299
Anesthesia, Local, Biliary Tract Diseases
Olsztyn, Warmian-Masurian Voivodeship, Poland
View Trial DetailsNCT07329933
Cholecystectomy, Laparoscopic, Dexamethasone
Banhā, Egypt
View Trial DetailsNCT07454629
Bispectral Index Variability During General Anesthesia and Postoperative Recovery, Cholecystectomy, Laparoscopic
Sakarya, Serdivan, Turkey (Türkiye)
View Trial DetailsNCT07119203
Benign Gallbladder Disease, Biliary Tract Diseases
Portsmouth, United Kingdom
View Trial Details